Markets:

Overview

News

Currencies

International

Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

126.15 +1.15 (+0.92%)

Streaming Delayed Price Updated: 9:46 AM EDT, Jun 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

April 03, 2024

From Glaukos Corporation

Via Business Wire

Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

April 01, 2024

From Glaukos Corporation

Via Business Wire

5 Analysts Have This To Say About Glaukos ↗

March 22, 2024

Via Benzinga

Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday ↗

February 22, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Glaukos: Q4 Earnings Insights ↗

February 21, 2024

Via Benzinga

Earnings Scheduled For February 21, 2024 ↗

February 21, 2024

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.

Via Benzinga

Analyst Ratings For Glaukos ↗

February 16, 2024

Via Benzinga

Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results

February 21, 2024

From Glaukos Corporation

Via Business Wire

Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21

January 31, 2024

From Glaukos Corporation

Via Business Wire

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance

January 09, 2024

From Glaukos Corporation

Via Business Wire

Glaukos' Newly Approved Glaucoma Treatment Is The 'Biggest Driver To Watch': Analyst ↗

December 21, 2023

Shares of Glaukos Corp (NYSE: GKOS) continued to climb in early trading on Thursday, after the company’s iDose TR (travoprost intracameral implant) received U.S.

Via Benzinga

Unveiling 7 Analyst Insights On Glaukos ↗

December 21, 2023

Via Benzinga

Analyst Ratings for Glaukos ↗

November 28, 2023

Via Benzinga

4 Analysts Have This to Say About Glaukos ↗

November 08, 2023

Via Benzinga

Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday ↗

December 21, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

December 20, 2023

From Glaukos Corporation

Via Business Wire

iDoseTR Approval Sets Stage for Glaukos' Game-Changing Product, Surpassing Market Expectations, Says Analyst ↗

December 15, 2023

Thursday, the FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog...

Via Benzinga

Dow Extends Rally As Treasury Yields Tank ↗

December 14, 2023

The Dow Jones Industrial Average is charging full speed ahead, up 78 points this afternoon after yesterday closing at record highs, on the heels of the Federal Reserve's rate decision.

Via Talk Markets

Topics Economy Stocks

8 Analysts Have This to Say About Glaukos ↗

September 26, 2023

Via Benzinga

Glaukos's Earnings Outlook ↗

August 01, 2023

Via Benzinga

Analyst Ratings for Glaukos ↗

July 31, 2023

Via Benzinga

FDA Approves Glaukos' Eye Implant To Treat Eye Pressure In Glaucoma Patients ↗

December 14, 2023

The FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for...

Via Benzinga

Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)

December 14, 2023

From Glaukos Corporation

Via Business Wire

Glaukos Announces Participation in Stifel Healthcare Conference

November 07, 2023

From Glaukos Corporation

Via Business Wire

Glaukos Announces Third Quarter 2023 Financial Results

November 01, 2023

From Glaukos Corporation

Via Business Wire

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting

October 31, 2023

From Glaukos Corporation

Via Business Wire

Glaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023

October 11, 2023

From Glaukos Corporation

Via Business Wire

Glaukos Announces Participation in Wells Fargo Healthcare Conference

August 23, 2023

From Glaukos Corporation

Via Business Wire

Glaukos Announces Second Quarter 2023 Financial Results

August 02, 2023

From Glaukos Corporation

Via Business Wire

Glaukos Poised To Surpass Expectations And Raise Outlook In Q2 FY23, Fueled By iStent And iAccess Launches: Analyst ↗

July 19, 2023

Needham expects Glaukos Corp (NYSE: GKOS) to surpass expectations and raise outlook in Q2 FY23, fueled by rebounding iStent inject volumes post-2022 reimbursement-driven declines. An additional upside...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.